AI in Medicine — Cancer & Rare Disease — 2026-09-25 (Fri) Morning News

Daily ReportMorning edition, 06:10 JST

Source links point to the original outlet. The AI Integrated Analysis is auto-generated from the headlines below only and is not intended to add facts beyond them. Not investment advice.

Editions of the day： Morning News (Morning 06:10)

🌅 Morning Report06:17 JST

Source: Google News RSS / regulators and societies / ClinicalTrials.gov / YouTube · 過去48時間以内 · 21 articles

Movement was concentrated in the diagnostic/imaging field (breast cancer screening, prediction of complications related to lung treatment, esophageal cancer screening, radiology AI utilization).

Latest news on AI and cancer treatment

Overview

Movement was concentrated in the diagnostic/imaging field (breast cancer screening, prediction of complications related to lung treatment, esophageal cancer screening, radiology AI utilization). In the drug discovery field, while there were topics about the preclinical and exploration stages, such as the expansion of AbbVie's partnership, there were no headlines about new approvals or designations by regulatory authorities (FDA, EMA, PMDA).

Breast cancer

- An AI model that integrates multiple modalities (ultrasound + digital breast tomosynthesis) was reported to improve specificity in breast cancer screening triage (News-Medical, EurekAlert!). The target population and stage of evidence (preclinical/single-center retrospective/randomized controlled trial, etc.) are unclear from the headline. - There was a report that Israeli researchers are promoting the use of AI for cancer treatment and diagnosis (Jewish Telegraphic Agency). The specific method and results are unknown.

lung cancer

- It has been reported that an AI model using regular CT images may be able to identify patients at risk of severe lung inflammation associated with treatment (therapy-induced pneumonitis) (Newswise). The target and evidence stage are unclear from the headline. - There was a report that AI evaluates cardiovascular risk using regular CT images (Cardiovascular Business). The headline does not clearly indicate a direct relationship with cancer types. - It was reported that an AI model for esophageal cancer screening has been developed in China (СБ Беларусь). Although the topic is esophageal cancer rather than lung cancer, it was added because it was classified in this article group. Detailed accuracy and stage are unknown.

Malignant brain tumor

It was reported in 2 Minute Medicine that large-scale language models (LLMs) were able to generate accurate content in the production of research manuscripts, but that more complex analyzes required human supervision. Please note that this is a report on research writing support, not on brain tumor imaging diagnosis or treatment planning itself.

Leukemia/lymphoma

No applicable information

Colon cancer/digestive organ

It was reported that BigHat has raised $75 million as AI-designed biologics enter the clinic (FirstWord). The target disease and clinical stage (phase, etc.) are unclear from the headline. It is not specified whether the content is specific to colorectal cancer.

Rare cancer

There was a report that Ambitious Bio is creating a proteomics (protein expression) dataset for research and drug discovery using AI (GenomeWeb). Although the classification in the headline states that the disease falls under the category of "adenoid cystic carcinoma," the details of the target cancer type and stage are unclear in the text of the article.

Diagnosis/Pathology/Image

- It was reported that AI outperformed standard methods in predicting organ failure in patients with acute pancreatitis (Radiology Business). The evidence stage is unclear from the headline. - Announced that Leica Biosystems has added Tempus' oncology AI tools to the Aperio AI Store (clpmag.com). This is a product integration announcement, and there is no mention of clinical results. - There was an editorial article about the rise of "AI-native radiology treatment" (STAT). - There was a report that a radiology startup is combining medical practice and AI development (UA.NEWS, STAT). - There was a report that cancer-related questions were the top questions asked to AI doctors in nine countries (KTEN).

Treatment selection/drug discovery

- It was announced that AbbVie will partner with Iambic to accelerate AI drug discovery in the fields of immunology, neuroscience, and oncology (Pulse 2.0). The stage appears to be preclinical/exploratory, but the heading does not specify this. - AbbVie is reportedly expanding AI drug discovery through new partnerships and industry initiatives (simplywall.st). - There was an article discussing whether AI can actually save lives (Vox). It does not report specific clinical trial or product results. - There was an article (36kr.com) discussing the main limitations and practical challenges of AlphaFold's inability to solve the challenges of AI drug discovery. The content is critical and analytical, and does not contain new empirical data.

Regulations/Approval

No applicable information

Clinical trial implementation status

Information regarding the specific trial name, target cancer type, phase, and registration status from ClinicalTrials.gov was not included in the input data. We do not make assumptions about the number or status of cases.

Japanese movements

There was an article called "Artificial Intelligence in Genomics Manufacturer Ranking" (pando.life). The specific details of the use of AI in cancer treatment in Japan are unclear from the headline.

Remarks from VIPs

No relevant information (The list of important people being tracked is also blank, so statements are not linked)

Latest news on AI and rare and incurable diseases

Overview

Only one headline was collected this time, and it was about genetic analysis and genome-related funding. No headlines indicating specific developments regarding diagnostics, therapeutic drugs, or systems could be confirmed.

Diagnosis of rare diseases

No applicable information

Gene analysis/genome

Codebreaker Labs has reportedly raised $4.5 million in seed funding to build a data infrastructure for genome analysis AI (source: Dealroom). The headline does not indicate specific verification results for the target disease or technology (mutation interpretation accuracy, diagnostic rate, etc.) and is limited to information at the funding stage. A direct relationship with rare and intractable diseases cannot be confirmed from the headline.